Response to "Conversion surgery as a missing outcome in first-line immunotherapy trials for hepatocellular carcinoma". Su YY, Hsu C. J Hepatol 2026 Mar 17:S0168-8278(26)00139-X. doi: 10.1016/j.jhep.2026.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Su YY, Hsu C. Response to "Conversion surgery as a missing outcome in first-line immunotherapy trials for hepatocellular carcinoma". J Hepatol 2026 Mar 17:S0168-8278(26)00139-X. doi: 10.1016/j.jhep.2026.
PMID: 41856413